Skip to main content

Table 3 Experimental design layout and observed responses for trospium chloride ER tablets

From: Development, optimization and pharmacokinetic evaluation of biphasic extended-release osmotic drug delivery system of trospium chloride for promising application in treatment of overactive bladder

Batches Factor A Factor B Factor C Factor D Response
Polyethylene oxide Cellulose Acetate Polyethylene glycol 6000 Orifice diameter % drug release at 2 h (Acid stage) % drug release at 5 h (Buffer stage) % drug release at 11 h (Buffer stage) % drug release at 20 h (Buffer stage)
mg % ratio % ratio mm % % % %
TSP1 250 94 6 0.6 20 42 66 97
TSP2 250 94 6 0.6 18 43 65 96
TSP3 300 97 3 0.5 4 19 46 96
TSP4 200 91 3 0.5 10 25 65 100
TSP5 200 97 9 0.5 14 32 76 98
TSP6 200 91 9 0.7 42 65 82 100
TSP7 300 91 3 0.5 12 22 50 95
TSP8 300 91 9 0.5 14 52 70 94
TSP9 200 91 3 0.7 14 28 68 99
TSP10 300 97 9 0.5 12 32 58 95
TSP11 200 97 3 0.5 7 23 58 99
TSP12 300 97 3 0.7 5 17 43 92
TSP13 250 94 6 0.6 22 39 67 97
TSP14 300 97 9 0.7 15 36 61 93
TSP15 250 94 6 0.6 25 45 71 98
TSP16 300 91 3 0.7 10 27 50 92
TSP17 200 91 9 0.5 45 71 85 99
TSP18 300 91 9 0.7 19 43 65 96
TSP19 200 97 9 0.7 12 28 72 100
TSP20 200 97 3 0.7 8 21 60 100
  1. % Drug release values are expressed as mean where, n = 3